Skip to main content
. 2015 May 4;6(26):23008–23014. doi: 10.18632/oncotarget.3984

Figure 3. Evolution of angiogenic cytokines and regulatory T lymphocytes during maintenance therapy.

Figure 3

Evolution of Ang-2, VEGFR-1, VEGF and Treg levels was monitored at treatment initiation and after 6, 12 and 18 months of maintenance therapy and is shown in panels A., B., C. and D., respectively. Columns, mean value from 47 patients; Bars, SEM. Ang-2: Angiopoietin-2, VEGFR-1: Vascular Endothelial Growth Factor Receptor-1, VEGF: Vascular Endothelial Growth Factor, Treg: Regulatory T Lympocyte.